-
Something wrong with this record ?
LncRNAs LY86-AS1 and VIM-AS1 Distinguish Plasma Cell Leukemia Patients from Multiple Myeloma Patients
R. Bútová, P. Vychytilová-Faltejsková, J. Gregorová, L. Radová, M. Almáši, R. Bezděková, L. Brožová, J. Jarkovský, Z. Knechtová, M. Štork, L. Pour, S. Ševčíková
Language English Country Switzerland
Document type Journal Article
Grant support
NV18-03-00203
Ministry of Health
FNBr 65269705
Ministry of Health
MUNI/A/1698/2020
Ministry of Education Youth and Sports
NLK
Directory of Open Access Journals
from 2013
PubMed Central
from 2013
Europe PubMed Central
from 2013
ProQuest Central
from 2013-01-01
Open Access Digital Library
from 2013-01-01
ROAD: Directory of Open Access Scholarly Resources
from 2013
- Publication type
- Journal Article MeSH
Long non-coding RNAs (lncRNAs) are functional RNAs longer than 200 nucleotides. Due to modern genomic techniques, the involvement of lncRNAs in tumorigenesis has been revealed; however, information concerning lncRNA interplay in multiple myeloma (MM) and plasma cell leukemia (PCL) is virtually absent. Herein, we aimed to identify the lncRNAs involved in MM to PCL progression. We investigated representative datasets of MM and PCL patients using next-generation sequencing. In total, 13 deregulated lncRNAs (p < 0.00025) were identified; four of them were chosen for further validation in an independent set of MM and PCL patients by RT-qPCR. The obtained results proved the significant downregulation of lymphocyte antigen antisense RNA 1 (LY86-AS1) and VIM antisense RNA 1 (VIM-AS1) in PCL compared to MM. Importantly, these two lncRNAs could be involved in the progression of MM into PCL; thus, they could serve as promising novel biomarkers of MM progression.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22001344
- 003
- CZ-PrNML
- 005
- 20240926160809.0
- 007
- ta
- 008
- 220107s2021 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3390/biomedicines9111637 $2 doi
- 035 __
- $a (PubMed)34829867
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Bútová, Romana $u Babak Myeloma Group, Department of Pathophysiology, Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic $7 xx0322943
- 245 10
- $a LncRNAs LY86-AS1 and VIM-AS1 Distinguish Plasma Cell Leukemia Patients from Multiple Myeloma Patients / $c R. Bútová, P. Vychytilová-Faltejsková, J. Gregorová, L. Radová, M. Almáši, R. Bezděková, L. Brožová, J. Jarkovský, Z. Knechtová, M. Štork, L. Pour, S. Ševčíková
- 520 9_
- $a Long non-coding RNAs (lncRNAs) are functional RNAs longer than 200 nucleotides. Due to modern genomic techniques, the involvement of lncRNAs in tumorigenesis has been revealed; however, information concerning lncRNA interplay in multiple myeloma (MM) and plasma cell leukemia (PCL) is virtually absent. Herein, we aimed to identify the lncRNAs involved in MM to PCL progression. We investigated representative datasets of MM and PCL patients using next-generation sequencing. In total, 13 deregulated lncRNAs (p < 0.00025) were identified; four of them were chosen for further validation in an independent set of MM and PCL patients by RT-qPCR. The obtained results proved the significant downregulation of lymphocyte antigen antisense RNA 1 (LY86-AS1) and VIM antisense RNA 1 (VIM-AS1) in PCL compared to MM. Importantly, these two lncRNAs could be involved in the progression of MM into PCL; thus, they could serve as promising novel biomarkers of MM progression.
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Vychytilová-Faltejsková, Petra $u Babak Myeloma Group, Department of Pathophysiology, Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic $u Department of Molecular Medicine, Central European Institute of Technology (CEITEC), Masaryk University, 625 00 Brno, Czech Republic
- 700 1_
- $a Gregorová, Jana $u Babak Myeloma Group, Department of Pathophysiology, Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic
- 700 1_
- $a Radová, Lenka $u Department of Molecular Medicine, Central European Institute of Technology (CEITEC), Masaryk University, 625 00 Brno, Czech Republic
- 700 1_
- $a Almáši, Martina $u Department of Clinical Hematology, University Hospital Brno, 625 00 Brno, Czech Republic
- 700 1_
- $a Bezděková, Renata $u Department of Clinical Hematology, University Hospital Brno, 625 00 Brno, Czech Republic
- 700 1_
- $a Brožová, Lucie $u Institute of Biostatistics and Analyses (IBA), Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic
- 700 1_
- $a Jarkovský, Jiří $u Institute of Biostatistics and Analyses (IBA), Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic
- 700 1_
- $a Knechtová, Zdeňka $u Clinic of Internal Medicine, Hematology and Oncology, University Hospital Brno, 625 00 Brno, Czech Republic
- 700 1_
- $a Štork, Martin $u Clinic of Internal Medicine, Hematology and Oncology, University Hospital Brno, 625 00 Brno, Czech Republic
- 700 1_
- $a Pour, Luděk $u Clinic of Internal Medicine, Hematology and Oncology, University Hospital Brno, 625 00 Brno, Czech Republic
- 700 1_
- $a Ševčíková, Sabina $u Babak Myeloma Group, Department of Pathophysiology, Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic $u Department of Clinical Hematology, University Hospital Brno, 625 00 Brno, Czech Republic
- 773 0_
- $w MED00205373 $t Biomedicines $x 2227-9059 $g Roč. 9, č. 11 (2021)
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/34829867 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20220107 $b ABA008
- 991 __
- $a 20240926160803 $b ABA008
- 999 __
- $a ind $b bmc $g 1745443 $s 1152491
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 9 $c 11 $e 20211108 $i 2227-9059 $m Biomedicines $n Biomedicines $x MED00205373
- GRA __
- $a NV18-03-00203 $p Ministry of Health
- GRA __
- $a FNBr 65269705 $p Ministry of Health
- GRA __
- $a MUNI/A/1698/2020 $p Ministry of Education Youth and Sports
- LZP __
- $a Pubmed-20220107
